The HCC Kidney Cancer SPORE has been funded for two cycles since 2003. HCC is comprised of the following institutions: Beth Israel-Deaconess Medical Center (BIDMC); Dana- Farber Cancer Institute (DFCI); Harvard Medical School; Harvard School of Public Health; Brigham and Women’s Hospital; Massachusetts General Hospital (MGH); and Children’s Hospital of Boston. In addition to the institutions in the HCC, the Georgetown-Lombardi Cancer Center (GLCC) is collaborating institutions in this grant. The HCC Kidney Cancer SPORE has its administrative base at the BIDMC. Dr. David McDermott, who has led the HCC Kidney Cancer Program and SPORE since 2012 is joined as SPORE Director by Dr. William Kaelin, a laboratory scientist at DFCI and has served with Dr. McDermott as Director of the SPORE since early 2014. Dr. Kaelin is a world renowned basic and translational investigator with longstanding interest in renal cancer and a leader within the HCC community. The HCC Kidney Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of HCC.

The SPORE features three projects which address critical problems in kidney cancer and have translational components, which are supported by three cores, a developmental research program and a career enhancement program.

If you are interested in becoming involved in the Kidney Cancer SPORE program, please contact: